Incubate Joins Rep. Deborah Ross (D-N.C.), Biotech CEOs for Roundtable Discussion

Incubate's policy director John Guy recently sat down with Rep. Deborah Ross (D-N.C.) and several biotech executives for a roundtable discussion on policies impacting the future of life sciences innovation in North Carolina and across the country. NovaQuest Capital Management hosted the discussion.

Speakers discussed how the pill penalty, "Most Favored Nation" drug pricing policies, and cuts to the FDA and NIH risk stifling biotech innovation. According to Incubate's latest survey of early-stage biotech CEOs:

• 67% say the pill penalty has already chilled capital formation for small-molecule research and development.

• 78% warn that agency personnel changes at NIH, FDA, and HHS threaten their ability to complete clinical trials.

• The majority say below-cost reimbursement structures lead to negative outlooks for companies, indicating that foreign reference pricing models like "Most Favored Nation" would further threaten investment in the sector.

Learn more about what industry leaders are saying in Incubate's early-stage biotech CEO survey here.